Chairman & CEO
Tim Tyson is a world-renowned pharmaceutical industry leader. In his 35-plus year career, he has negotiated complex multi-billion-dollar mergers and acquisitions, led major turnarounds that have fueled growth and value, and, most significantly, has been instrumental in bringing more than 50 life-saving and life-improving medicines to market.
Prior to establishing TriRx, Mr. Tyson served as Chairman and CEO of Avara Pharmaceutical Services, Chairman and CEO of Aptuit, and CEO of Valeant Pharmaceuticals International. Earlier in his career, he spent 15 years at GlaxoSmithKline, starting in engineering, then commercial operations, and eventually becoming president of the company’s global manufacturing and supply division. Mr. Tyson began his career as a manufacturing manager at Procter & Gamble after completing full-time military service. He is a graduate of the United States Military Academy at West Point and received his M.B.A. and M.P.A. from Jacksonville State University.
Director & COO
Jim Scandura has a wealth of pharmaceutical industry experience through projects with i-Solutions, a specialty life science consulting company. He has managed three major pharmaceutical manufacturing network change programs, three consent decree recovery efforts, over 30 manufacturing site audit and operational improvement efforts, the integration of a large R&D center and the direct management and integration of several manufacturing sites.
Prior to TriRx, Mr. Scandura held senior roles at several major pharmaceutical companies, including Avara, Bristol Myers Squibb, GSK, Roche, Valeant, Patheon and Aptuit. Earlier in his career, he was Senior Vice President for Johnson Controls Inc. and, prior to that, served in the United States Navy Nuclear Submarine Service. He holds a B.S. in engineering from the University of the State of New York.
Director & CFO
Keith Lyon has over 35 years of experience in leadership positions in operational and transactional finance, both at world-class multinationals and smaller companies. Over the course of his career, he has completed numerous acquisitions and complex debt financings as well as two initial and two secondary public offerings.
Prior to co-founding TriRx, Mr. Lyon served as Chief Financial Officer and Head of Business Development of Avara Pharmaceutical Services. Prior to that he was CEO of a community bank, where he led a financial and regulatory recovery and negotiated a merger with a larger institution. Earlier in his career, he was an Operating Partner in private equity, during which time he supported the acquisition of Wise Snacks and served as interim CFO. He served as Corporate Treasurer for Estee Lauder and, earlier, Duracell, where he built a global treasury organization. Mr. Lyon began his career at Nestle in the United States and Brazil after which he was a senior corporate banker in Chicago and New York. He received his B.A. from the University of Leeds and his M.B.A. from the Booth School of Business at the University of Chicago.
EVP, Chief Client Services Officer
Mike Kays has extensive experience in project management, supply chain, operations and customer stewardship. He has been recognized for his expertise across many industries, including process equipment, cryogenics, cold chain technology and pharmaceutical manufacturing, including isolation and high-containment systems.
Prior to TriRx, Mr. Kays was Executive Vice President of Strategy and Supply for Avara Pharmaceutical Services and, earlier, Executive Vice President of Global Operations Planning for Aptuit. Previously, he was Senior Vice President of Global Supply for Valeant Pharmaceuticals, where he led a manufacturing restructuring and global outsourcing initiative. Earlier in his career, he served as CEO for a leading supplier of custom design/build equipment for major pharmaceutical customers across the Americas, Europe and Asia. Mr. Kays is a former board member of the ISPE International Leadership Forum and a current board member and executive advisor to various academic and business interests. He holds a B.S. degree from Alfred University in New York.
EVP, Chief Quality & Regulatory Officer
Donald Britt has over 40 years of experience in the pharmaceutical industry, primarily in quality and regulatory affairs.
Prior to TriRx, Mr. Britt held several senior quality positions, including Senior Vice President of Global Quality for Rhone Poulenc Rorer, Senior Vice President of Global Quality and EH&S for Aventis Pharma, Senior Vice President of Global Quality for Centocor Biologics, and Senior Vice President of Global Quality for Watson (Allergan). He has also held various positions of increasing responsibility within quality at GSK and, earlier, was Manufacturing Manager for Bayer Biologics. Mr. Britt began his pharmaceutical career working in the analytical laboratory at Baxter Travenol. He has a degree in biochemistry from the University of South Carolina.
EVP, Chief Human Resources Officer
Rick Mark's career has spanned five industries, including pharmaceuticals, distribution, consumer products and nuclear power generation. Throughout his career, he has led human resources due diligence/integration efforts resulting in acquisitions valued at $1 billion and covering 10,000 employees in 40 countries.
Mr. Mark has extensive experience in change management, mergers and acquisitions and leadership development. In previous roles, he led safety, health and facilities departments in addition to human resources for global organizations. Mr. Mark is also a recognized public speaker on workplace violence prevention. He has a B.A. from the University of North Carolina at Chapel Hill.
VP, Contracts and Global Procurement
Mark Owen is a seasoned pharmaceutical operations and supply chain executive, having held several senior global supply roles across various organizations.
Prior to TriRx, Mr. Owen managed procurement activities for Novartis’ external manufacturing division, which afforded him a deep understanding of customer expectations when outsourcing to a CDMO. Before Novartis, Mr. Owen held supply and operations leadership roles at Aptuit and, earlier, Valeant Pharmaceuticals. Earlier in his career, he served in an operations leadership role for a leading manufacturer of state-of-the-art isolators and downflow booths for major pharmaceutical companies. He began his career as a plant engineer for the specialty chemicals company Elf Atochem, where he progressed to Group Engineering Manager. Mr. Owen holds a B.Eng (Hons) in mechanical engineering from Liverpool John Moores University and an M.B.A. from the University of Bradford.
Jeremy Tatum has more than 18 years of commercial experience in the pharmaceutical industry.
Prior to TriRx, Mr. Tatum served as VP, Commercial and Portfolio for SunGen Pharma, where he managed multiple licensing deals in the US and abroad. Before SunGen, he ran the global serialization project for Par Pharmaceutical, a project that spanned five manufacturing locations, two distribution centers and over 30 CMOs. He joined Par Pharmaceutical as Director of Sales Operations following the company’s merger with Qualitest Pharmaceuticals, where he spent 14 years in roles of increasing responsibility, including Sales Representative, Sales and Marketing Manager, and, finally, Director of Market Insights, a role in which he strongly supported the company’s growth from $250 million to over $1.2 billion in net sales through multiple BD deals, AG launches and licensing agreements. Mr. Tatum grew up working in his family’s independent pharmacies and holds a B.S. degree in marketing from Tennessee Technological University.